The stock of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) is a huge mover today! About 155,301 shares traded hands or 169.60% up from the average. MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) has declined 33.01% since April 14, 2016 and is downtrending. It has underperformed by 37.70% the S&P500.
The move comes after 6 months positive chart setup for the $24.68M company. It was reported on Nov, 16 by Barchart.com. We have $9.58 PT which if reached, will make NASDAQ:MBVX worth $34.55 million more.
According to Zacks Investment Research, “MabVax Therapeutics Holdings, Inc. is a clinical-stage drug development company. It is focused on discovering and developing small molecule drugs to treat cancer. TELINTRA is the Company’s lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. MabVax Therapeutics Holdings, Inc., formerly known as Telik, Inc., is based in San Diego, California.”
More notable recent MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) news were published by: Prnewswire.com which released: “MabVax Therapeutics to Hold Conference Call to Provide Corporate Update On …” on November 14, 2016, also Seekingalpha.com with their article: “MabVax Therapeutics: Opportunity In Unmet Cancer Need” published on November 16, 2016, Prnewswire.com published: “MabVax Therapeutics Announces Uplisting to The Nasdaq Capital Market and $8 …” on August 17, 2016. More interesting news about MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) were released by: Prnewswire.com and their article: “MabVax Therapeutics Reports Third Quarter 2016 Financial Results and Schedules …” published on November 10, 2016 as well as Prnewswire.com‘s news article titled: “Oncology Biotech Standout MabVax Therapeutics Interviewed on Small Cap Nation” with publication date: September 16, 2016.
MBVX Company Profile
MabVax Therapeutics Holdings, Inc., incorporated on October 20, 1988, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery, development and commercialization of human monoclonal antibody products and vaccines for the diagnosis and treatment of various cancers. The Firm has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients immunized against targeted cancers. The Company’s lead antibody candidate, HuMab-5B1, is being developed as a therapeutic product and as a diagnostic imaging product. The antibody targets carbohydrate antigen sialyl Lewisa (sLea), which is expressed on tumors of the gastrointestinal tract, including pancreatic, colon and stomach cancers, as well as ovarian, breast and small cell lung cancers. The Firm is also developing the HuMab-5B1 antibody conjugated to a radiolabel as a positron emission tomography (PET) imaging agent to assist in the diagnosis of pancreatic cancer. It also discovered and is developing multiple fully-human antibodies to the antigen disialoganglioside (GD2).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.